Results 11 to 20 of about 2,050 (152)

Emergence of eravacycline heteroresistance in carbapenem-resistant Acinetobacter baumannii isolates in China [PDF]

Frontiers in Cellular and Infection Microbiology
Carbapenem-resistant Acinetobacter baumannii (CRAB) is resistant to almost all antibiotics. Eravacycline, a newer treatment option, has the potential to treat CRAB infections, however, the mechanism by which CRAB isolates develop resistance to ...
Zhi-Wei Lin
exaly   +4 more sources

Resistance of Gram-Negative Bacteria to Eravacycline: A Systematic Review of Data from In Vitro Studies [PDF]

Pathogens
Introduction: Eravacycline is a new fluorocycline antibiotic with a broad spectrum of antimicrobial activity approved for the treatment of patients with complicated intra-abdominal infections.
Matthew E. Falagas, Laura T. Romanos, Dimitrios S. Kontogiannis, Charalampos Filippou, Drosos E. Karageorgopoulos   +4 more
doaj   +4 more sources

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland

Biomedicines, 2023
Eravacycline is a novel antibiotic of the tetracycline class with activity against a broad spectrum of clinically significant bacteria, including multi-drug-resistant organisms. For this reason, it may be an alternative to treating critical infections of
Małgorzata Brauncajs, Filip Bielec, Anna Macieja, Dorota Pastuszak-Lewandoska   +3 more
doaj   +2 more sources

In vitro activity of eravacycline, a novel synthetic halogenated tetracycline, against the malaria parasite Plasmodium falciparum

Journal of Global Antimicrobial Resistance, 2021
Objectives: Eravacycline is a novel synthetic halogenated tetracycline derivative with a broad antibacterial spectrum. Antibiotics, including tetracyclines, have been used for prophylaxis and, more rarely, for the treatment of malaria for several decades.
Erik Koehne, Andrea Kreidenweiss, Bayode Romeo Adegbite, Rella Zoleko Manego, Matthew B.B. McCall, Ghyslain Mombo-Ngoma, Ayola Akim Adegnika, Sélidji Todagbé Agnandji, Benjamin Mordmüller, Jana Held   +9 more
doaj   +2 more sources

Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates

Antibiotics, 2022
For decades, the spread of multidrug-resistant (MDR) Acinetobacter baumannii has been rampant in critically ill, hospitalized patients. Traditional antibiotic therapies against this pathogen have been failing, leading to rising concerns over management ...
Manas S. Deolankar, Rachel A. Carr, Rebecca Fliorent, Sean Roh, Henry Fraimow, Valerie J. Carabetta   +5 more
doaj   +2 more sources

Development and Validation of a Rapid LC-MS/MS Method for Quantifying Eravacycline in Epithelial Lining Fluid: Application to a Prospective Pulmonary Distribution Study in HAP/VAP Patients [PDF]

Antibiotics
Background: Eravacycline exhibits potent activity against multidrug-resistant pathogens and holds promise for the management of hospital-acquired and ventilator-associated pneumonia (HAP/VAP).
Jingjing He, Jingjing Lin, Xin Li, Nanyang Li, Jianguang Su, Jufang Wu, Jin Hu, Jing Zhang, Xiaofen Liu   +8 more
doaj   +2 more sources

Evaluation of the synergistic effect of eravacycline and tigecycline against carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae

Journal of Infection and Public Health
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a substantial healthcare challenge. This study assessed the in vitro efficacy of selected antibiotic combinations against CRKP infections.
Yu-Shan Huang, Jia-Ling Yang, Jann-Tay Wang, Wang-Huei Sheng, Chia-Jui Yang, Yu-Chung Chuang, Shan-Chwen Chang   +6 more
doaj   +2 more sources

Assessment of Eravacycline Antimicrobial Susceptibility in China During the First Year Following Regulatory Approval (2023–2024): A Real-World Study [PDF]

Microorganisms
Eravacycline, a novel fluorocycline antimicrobial, was approved by China’s National Medical Products Administration (NMPA) in March 2023; however, clinical breakpoints and real-world data on its use in China remain limited.
Qiaolian Yi, Yi Li, Menglan Zhou, Ran Jing, Minya Lu, Yingchun Xu   +5 more
doaj   +2 more sources

Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium abscessus lung disease [PDF]

Microbiology Spectrum
Treatment of Mycobacterium abscessus (MAB) pulmonary diseases is challenging due to intrinsic resistance to many antibiotics and requires prolonged intravenous therapy with drugs that have severe side effects.
Sanjay Singh, Avneesh Shrivastava, Gunavanthi D. Boorgula, Mary C. Long, Brian Robbins, Tawanda Gumbo, Shashikant Srivastava   +6 more
doaj   +2 more sources

Real-World Experience on the Use of Eravacycline at Doses of 1 mg/kg Bodyweight and Fixed Dose Strategy in Two European Tertiary Centers [PDF]

Antibiotics
Background: Eravaycline is a novel fully synthetic fluorocycline that is currently approved for complicated intra-abdominal infections. However, it is sometimes also used off-label in tertiary care centers for other infection sites as an antibiotic of ...
Karin Oberreiter, Miriam M. Moser, Lisa Schneider, Heinz Burgmann, Chiara Moreal, Simone Giuliano, Jacopo Angelini, Carlo Tascini, Matthias G. Vossen   +8 more
doaj   +2 more sources